Praxis and Relmada target depression as Athira and Taurx tackle Alzheimer’s.
Resmetirom’s first pivotal liver disease study reminds the markets about the third quarter’s Nash readout, but investors wanted more.
Ipsen hopes to draw a line under its earlier deal-making snafu with a bet on Genfit, and investors have just over a year’s wait for the proof.
A rollercoaster year for biopharma ended with investors firmly deciding that the pandemic was an opportunity, not a threat.
Intercept’s woes have continued as a possible new liver toxicity signal was buried in a regulatory filing. What could this mean?
An analysis of FDA complete response letters does not reveal a big uptick – but the year is not over yet.
Encouraging cholangitis data follows the lifting of a clinical hold on Cymabay’s seladelpar, signalling a way forward for a project that looked finished.